Renaissance Technologies LLC Buys 135,200 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Renaissance Technologies LLC lifted its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 170.9% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 214,300 shares of the company’s stock after purchasing an additional 135,200 shares during the quarter. Renaissance Technologies LLC’s holdings in Syndax Pharmaceuticals were worth $4,400,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Kynam Capital Management LP increased its stake in Syndax Pharmaceuticals by 41.5% in the 4th quarter. Kynam Capital Management LP now owns 5,660,000 shares of the company’s stock worth $122,313,000 after buying an additional 1,660,000 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Syndax Pharmaceuticals by 13.6% in the first quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company’s stock valued at $117,262,000 after acquiring an additional 591,631 shares in the last quarter. Avoro Capital Advisors LLC grew its position in shares of Syndax Pharmaceuticals by 65.2% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,222,222 shares of the company’s stock worth $91,242,000 after purchasing an additional 1,666,667 shares in the last quarter. Avidity Partners Management LP raised its stake in Syndax Pharmaceuticals by 40.0% during the 4th quarter. Avidity Partners Management LP now owns 3,950,000 shares of the company’s stock valued at $85,360,000 after purchasing an additional 1,129,000 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in Syndax Pharmaceuticals by 35.3% in the 4th quarter. Point72 Asset Management L.P. now owns 2,834,499 shares of the company’s stock worth $61,254,000 after purchasing an additional 740,298 shares in the last quarter.

Analyst Ratings Changes

Several research analysts have commented on SNDX shares. JPMorgan Chase & Co. dropped their price objective on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Bank of America lifted their target price on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. Stifel Nicolaus lifted their price target on shares of Syndax Pharmaceuticals from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, June 26th. Jefferies Financial Group initiated coverage on Syndax Pharmaceuticals in a report on Friday, June 28th. They issued a “buy” rating and a $37.00 price target on the stock. Finally, Barclays upped their price objective on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a research report on Thursday, August 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $35.33.

Syndax Pharmaceuticals Trading Up 4.0 %

Shares of SNDX opened at $18.89 on Friday. The firm has a market cap of $1.61 billion, a PE ratio of -5.87 and a beta of 0.91. The stock has a fifty day moving average price of $20.16 and a 200-day moving average price of $20.99. Syndax Pharmaceuticals, Inc. has a 12 month low of $11.22 and a 12 month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.11. The company had revenue of $3.50 million for the quarter. During the same quarter in the previous year, the business earned ($0.64) earnings per share. Syndax Pharmaceuticals’s revenue was up 3499999990.0% on a year-over-year basis. As a group, research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.66 EPS for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).